Visterra closes $26m Series A, to take flu antibody into clinic
This article was originally published in Scrip
Fresh off a drug discovery deal with Pfizer, infectious disease-focused Visterra has raised $13 million to complete a $26 million Series A venture financing round to advance VIS410, a broad spectrum monoclonal antibody for the prevention and treatment of seasonal and pandemic influenza, and potentially another drug candidate into clinical development.
You may also be interested in...
After eptinezumab’s approval in the US, EVP Peter Anastasiou told Scrip it will take time to change migraine doctors’ prescribing habits, but he expects CGRP inhibitors to become mainstay preventative treatments. Vyepti’s list price is about $1,000 below its competitors’ launch prices.
ICER’s final report on new acute migraine treatments said the drugs are similarly beneficial when patients don’t respond to or can’t take triptans, but found Reyvow is not as cost effective as Ubrelvy and rimegepant.
CEO Richard Pops said the company will leverage in-house expertise for internally and externally developed neuroscience assets, but partner selectively to advance its IL-2 protein in cancer.